MediSynergics LLC

WHO WE ARE!

Dennis M. Godek, M.A. Chem.,President, MediSynergics LLC

Dennis is an organic chemist with extensive experience in drug discovery and development. He has been involved with several marketed drugs, including the antipsychotic agent ziprasidone (Geodon (TM)), the oral antibiotic sultamicillin and other important new medications. More recently, he held positions of increasing management and supervisory responsibility within the Pharmaceutical Sciences, Project Management and Veterinary Sciences Departments. 

Dennis is listed as an inventor on 18 US patents and is a co-author of two peer-reviewed journal articles. He is a member of the American Chemical Society (ACS) and was a Captain in the USAF Reserves (ret.).

Harry R. Howard, Jr., M.S. Chem.,

Chief Scientific Officer (CSO)

Harry is a medicinal chemist with broad experience in drug discovery and development.   He co-discovered the atypical antipsychotic drug ziprasidone (Geodon (TM)) for the treatment of schizophrenia and mania, and the novel serotonin-1D antagonist elzasonan for the treatment of depression. During his career, he also developed expertise in the design of novel compounds for the treatment of Central Nervous System disorders, including schizophrenia, depression, and attention deficit hyperactivity disorder (ADHD), as well as medications to minimize the long-term complications of  chronic diabetes; these efforts resulted in the nomination of five additional development candidates. 

Harry is a member of the American Chemical Society (ACS) and is listed as an inventor on 57 U.S. patents and an author of 30 peer-reviewed publications.  He has served as an adjunct instructor of Medicinal Chemistry at St. Joseph College in West Hartford, CT. 

In 2005, he received the ACS Regional Industrial Innovation Award for his role in the development of Geodon and in 2007 was recognized as a Hero of Chemistry by the ACS.

He is featured in the article "A Quick Lift for the Blues" by Robert Langreth published in the August 2003 edition of Forbes Magazine.